Vivos Therapeutics Bags First Ever FDA 510(k) Clearance for Oral Device Treatment of Severe Obstructive Sleep Apnea
Portfolio Pulse from Benzinga Newsdesk
Vivos Therapeutics, Inc. has received FDA 510(k) clearance for its CARE oral appliances, designed to treat severe obstructive sleep apnea in adults. This includes the DNA, mRNA, and mmRNA oral appliances, marking a significant milestone for the company in the medical device and technology sector.
November 29, 2023 | 12:32 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Vivos Therapeutics' FDA clearance for its CARE oral appliances to treat severe OSA is a significant positive development, likely to boost investor confidence and potentially increase the company's market share in the sleep disorder treatment sector.
FDA approvals are critical milestones for medical device companies. The clearance of Vivos' CARE appliances is likely to be viewed positively by investors as it opens up market opportunities and validates the company's technology. This could lead to increased sales and partnerships, as well as a potential rise in stock price in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100